08:39 AM EST, 12/30/2025 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Tuesday it has closed its first syndicated credit facility, totaling $980 million and maturing in 2030.

The facility consists of a $580 million initial term loan, a $300 million delayed draw term loan, and a $100 million revolving credit facility, the company said.

Proceeds from the initial term loan were used to repay about $581 million of principal covering the full remaining balance of the company's prior $646 million term loan secured from funds managed by Pharmakon Advisors, the company said.

The delayed draw term loan and the revolving credit facility were undrawn at closing and are expected to be used for general corporate purposes, the company said.